Strong synergy is seen in neuronal, renal, breast, lung, and haematopoietic cancer cells harboring abnormalities in PTEN, VHL, LKB1, Her2, or KRAS. This evidence concerns the gene PTEN and hematopoietic and lymphoid cell neoplasm.